

The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans

Daniel R. Carrasco,^{1,3} Tim Fenton,² Kumar Sukhdeo,¹ Marina Protopopova,^{1,4} Miriam Enos,¹ Mingjian J. You,³ Dolores Di Vizio,¹ Cristina Nogueira,¹ Jayne Stommel,¹ Geraldine S. Pinkus,³ Christopher Fletcher,³ Jason L. Hornick,³ Webster K. Cavenee,² Frank B. Furnari,² and Ronald A. DePinho^{1,4,*}

¹Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115

²Ludwig Institute for Cancer Research, University of California, San Diego, School of Medicine, La Jolla, California 92093

³Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115

⁴Center for Applied Cancer Science, Belfer Foundation Institute for Innovative Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115

*Correspondence: ron_depinho@dfci.harvard.edu

(Cancer Cell 9, 379–390; May 2006)

In this article, coauthor Dolores Di Vizio was listed incorrectly as Dolores Divicio. The correct author list is printed above.

DOI: 10.1016/j.ccr.2006.07.012
